ENDRA Life Sciences Q4 EPS $(3.25) Misses $(1.95) Estimate

ENDRA Life Sciences (NASDAQ: NDRA) reported a Q4 loss of $(3.25) per share, missing the analyst consensus estimate of $(1.95) by 66.67%. This represents a 55.78% improvement compared to losses of $(7.35) per share from the same period last year.